Samarium 153 Lexidronam

What is Samarium 153 Lexidronam

Samarium-153 lexidronam is a parenteral radioisotope indicated for the relief of pain associated with metastatic bone cancer.

The onset of analgesic effect is usually within 7 days, with maximum pain relief generally occurring 3 to 4 weeks after administration.

It consists of a stable complex of radioactive samarium and a tetraphosphonate chelator, ethylenediaminetetramethylenephosphonic acid (EDTMP).

Brand Name

QUADRAMET

Indications

  • bone pain

Side Effects

  • abdominal pain
  • alopecia
  • anemia
  • angina
  • arrhythmia exacerbation
  • bone fractures
  • bone pain
  • bradycardia
  • candidiasis
  • chest pain (unspecified)
  • chills
  • coagulopathy
  • cough
  • diarrhea
  • disseminated intravascular coagulation (DIC)
  • dizziness
  • ecchymosis
  • epistaxis
  • fever
  • flushing
  • GI bleeding
  • heart failure
  • hematuria
  • hypertension
  • hypotension
  • infection
  • leukopenia
  • lymphadenopathy
  • myasthenia
  • nausea
  • ocular hemorrhage
  • paresthesias
  • purpura
  • rash
  • stroke
  • thrombocytopenia
  • vomiting

Monitoring Parameters

  • CBC
  • pregnancy testing

Contraindications

  • accidental exposure
  • anorexia nervosa
  • bone marrow suppression
  • breast-feeding
  • cardiac arrhythmias
  • chemotherapy
  • contraception requirements
  • disseminated intravascular coagulation (DIC)
  • heart failure
  • hypocalcemia
  • obesity
  • phosphonate hypersensitivity
  • pregnancy
  • pregnancy testing
  • radiation therapy
  • renal impairment
  • reproductive risk
  • urinary incontinence

Interactions

There are no drug interactions associated with Samarium-153 Lexidronam products.